Full-Time
Global health education, access, and research
$24 - $38/hr
No H1B Sponsorship
Memphis, TN, USA
In Person
| , |
Care Access coordinates global efforts to improve health by educating people about health, helping them access needed resources, and enabling participation in medical research to develop new medicines and cures. Its approach involves a global network and services that educate individuals, connect them with health resources, and recruit participants for clinical studies, thereby supporting the development of new treatments. Unlike companies that focus on a single market or product, Care Access operates worldwide and focuses on easing access to information, services, and research opportunities for diverse populations. The goal is to make health information and access more available and participation in health studies easier, with the aim of making the future of health better for everyone.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Boston, Massachusetts
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
People at Care Access who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Walmart, Care Access to partner on clinical research. Walmart will partner with Care Access to launch a clinical research initiative this spring that will bring clinical trial opportunities to markets, including rural areas that often lack access to cutting-edge medical research. The retailer will open research sites at select stores and former Walmart Health clinic locations. By using familiar community spaces, Walmart hopes to make participation in clinical research more accessible and convenient for local residents. Designed specifically for retail professionals, NRF SmartBrief is a free, daily email newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition.
On December 6th and 7th Firstfree is partnering with Care Access, an organization with a mission to connect the community with equitable health research.
BOSTON--(BUSINESS WIRE)--Care Access, a global clinical research site company helping to accelerate the future of medicine, has opened its newest research site in Warsaw, Poland. The company’s expansion in Poland reinforces its commitment to improving access to clinical research globally through its innovative model of bringing clinical trials wherever they are needed. In recent years, Care Access has been active in clinical research across Europe, and now, by establishing a new facility in Warsaw, Care Access is further expanding its European services aimed to implement its industry-leading research capabilities, such as its Community Screening Program, Sites On Demand, and Mobile Research Site Infrastructure. These capabilities have shown to accelerate research study enrollment by adapting to the unique makeup of each community and providing more convenient ways to participate in clinical trials. “Poland plays an important role in bringing the future of medicine to reality,” said Rupi Bancil, Senior Vice President of Global Study Operations Expansion for Care Access. “The Warsaw site will improve access to advanced health screenings and research opportunities to communities throughout Poland.”
BOSTON--(BUSINESS WIRE)--A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area. The SERENA-6 trial, sponsored by AstraZeneca, is a global study that aims to address a critical issue faced by many patients: their treatments become less effective over time. In advanced breast cancer, patients receive a treatment that combines an estrogen-reducing drug with a drug that slows cancer cell growth. While this combination works well, over time, it may stop working because of mutations in the ESR1 gene. This study will evaluate if an experimental trial drug, combined with a cancer-slowing drug, might work better than conventional estrogen-reducing drugs for patients with ESR1 mutations
BOSTON--(BUSINESS WIRE)--Adults in the Ogden, Utah area with moderately to severely active ulcerative colitis (UC) may have the opportunity to join a research study assessing a new investigational medication. UC is the most common form of inflammatory bowel disease (IBD), affecting an estimated 5 million people worldwide. There is no known cure for UC, though new therapies have become available in recent years that offer patients improved treatment options. Current treatments for UC offer relief for many individuals, but some still face recurrent flare-ups or undesirable side effects. The ANTHEM-UC study from Janssen Research Development seeks to assess if an investigational pill could help those patients whose UC is not adequately managed by currently available therapies. “Ulcerative colitis is a lifelong condition that often gets worse over time, potentially causing severe flare-ups or hospitalization,” said Dr